Title:The Therapeutic Significance of HER3 in Non-small Cell Lung
Cancer (NSCLC): A Review Study
Volume: 32
Issue: 3
Author(s): Amelia Trinder, Ke Ding*Jinwei Zhang*
Affiliation:
- State Key Laboratory of
Chemical Biology, Research Center of Chemical Kinomics, Shanghai Institute of Organic Chemistry, Chinese
Academy of Sciences, 345 Lingling Road, Shanghai 200032, China
- Hatherly Laboratories, Faculty of Health and Life Sciences, Medical School, Institute of Biomedical and
Clinical Sciences, University of Exeter, Streatham Campus, Exeter EX4 4PS, UK
- State Key Laboratory of
Chemical Biology, Research Center of Chemical Kinomics, Shanghai Institute of Organic Chemistry, Chinese
Academy of Sciences, 345 Lingling Road, Shanghai 200032, China
Keywords:
HER3, non-small cell lung cancer, monoclonal antibody, tyrosine kinase inhibitor, therapeutics, clinical trials.
Abstract: HER3 (Human Epidermal Growth Factor Receptor 3) is frequently overexpressed
in various cancers, including non-small cell lung cancer (NSCLC), with a prevalence
of 83% in primary tumors. Its involvement in tumorigenesis and resistance to targeted
therapies makes HER3 a promising target for cancer treatment. Despite being initially
considered “undruggable” due to its lack of catalytic activity, significant progress
has been made in the development of anti-HER3 therapeutics. Monoclonal antibodies
such as lumretuzumab, seribantumab, and patritumab have shown potential in targeting
HER3 to overcome resistance to epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs). Additionally, antibody-drug conjugates (ADCs) like HER3-DXd
(patritumab deruxtecan) are new drug candidates that have demonstrated selective delivery
of cytotoxic chemicals to NSCLC cells by exploiting HER3's widespread expression,
minimizing cytotoxicity. This review aims to evaluate the efficacy of current
HER3 therapeutics in development and their therapeutic potential in NSCLC, incorporating
evidence from clinical trials.
